Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CFO Joseph M. Miller Sells 61,859 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now directly owns 633,515 shares of the company’s stock, valued at $5,068,120. The trade was a 8.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $8.08 on Wednesday. The company has a market capitalization of $1.16 billion, a P/E ratio of -53.86 and a beta of 1.22. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The business has a 50 day simple moving average of $8.13 and a 200-day simple moving average of $7.85. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Large investors have recently modified their holdings of the company. SBI Securities Co. Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $27,000. Tower Research Capital LLC TRC lifted its holdings in shares of Aurinia Pharmaceuticals by 368.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 2,635 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $31,000. Finally, Natixis acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $49,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.